Cargando…
Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells
Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 inhibitory function. In this study, we aimed to show...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333482/ https://www.ncbi.nlm.nih.gov/pubmed/28255316 http://dx.doi.org/10.4103/1735-5362.199049 |
_version_ | 1782511722359160832 |
---|---|
author | Atari-Hajipirloo, Somayeh Nikanfar, Saba Heydari, Amir Kheradmand, Fatemeh |
author_facet | Atari-Hajipirloo, Somayeh Nikanfar, Saba Heydari, Amir Kheradmand, Fatemeh |
author_sort | Atari-Hajipirloo, Somayeh |
collection | PubMed |
description | Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 inhibitory function. In this study, we aimed to show the apoptotic effects of imatinib in combination with DMC in human HT-29 colorectal cancer (CRC) cells. HT-29 CRC cells were treated with IC(50) dose of imatinib (6.60 μM), DMC (23.45 μM), and their combination (half dose of IC(50)) for 24 h. The caspase-3 activity was estimated with colorimetric kit. The caspase-3 gene expression was evaluated by real-time PCR method. There was a significant up-regulation in caspase-3 enzyme activity and caspase-3 expression by imatinib and its half dose combination with DMC as compared to control. As a summary, the results of this study strongly suggest that half dose combination of imatinib with DMC induced apoptosis as potent as full dose imatinib in human HT-29 CRC cells, while minimizing undesired side effects related to imatinib mono-therapy. This study also pointed towards possible caspase-dependent actions of imatinib and DMC. |
format | Online Article Text |
id | pubmed-5333482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-53334822017-03-02 Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells Atari-Hajipirloo, Somayeh Nikanfar, Saba Heydari, Amir Kheradmand, Fatemeh Res Pharm Sci Original Article Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 inhibitory function. In this study, we aimed to show the apoptotic effects of imatinib in combination with DMC in human HT-29 colorectal cancer (CRC) cells. HT-29 CRC cells were treated with IC(50) dose of imatinib (6.60 μM), DMC (23.45 μM), and their combination (half dose of IC(50)) for 24 h. The caspase-3 activity was estimated with colorimetric kit. The caspase-3 gene expression was evaluated by real-time PCR method. There was a significant up-regulation in caspase-3 enzyme activity and caspase-3 expression by imatinib and its half dose combination with DMC as compared to control. As a summary, the results of this study strongly suggest that half dose combination of imatinib with DMC induced apoptosis as potent as full dose imatinib in human HT-29 CRC cells, while minimizing undesired side effects related to imatinib mono-therapy. This study also pointed towards possible caspase-dependent actions of imatinib and DMC. Medknow Publications & Media Pvt Ltd 2017-02 /pmc/articles/PMC5333482/ /pubmed/28255316 http://dx.doi.org/10.4103/1735-5362.199049 Text en Copyright: © 2017 Research in Pharmaceutical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Atari-Hajipirloo, Somayeh Nikanfar, Saba Heydari, Amir Kheradmand, Fatemeh Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title | Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title_full | Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title_fullStr | Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title_full_unstemmed | Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title_short | Imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human HT-29 colorectal cancer cells |
title_sort | imatinib and its combination with 2,5-dimethyl-celecoxibinduces apoptosis of human ht-29 colorectal cancer cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333482/ https://www.ncbi.nlm.nih.gov/pubmed/28255316 http://dx.doi.org/10.4103/1735-5362.199049 |
work_keys_str_mv | AT atarihajipirloosomayeh imatinibanditscombinationwith25dimethylcelecoxibinducesapoptosisofhumanht29colorectalcancercells AT nikanfarsaba imatinibanditscombinationwith25dimethylcelecoxibinducesapoptosisofhumanht29colorectalcancercells AT heydariamir imatinibanditscombinationwith25dimethylcelecoxibinducesapoptosisofhumanht29colorectalcancercells AT kheradmandfatemeh imatinibanditscombinationwith25dimethylcelecoxibinducesapoptosisofhumanht29colorectalcancercells |